About this trial
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 2) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.
Eligibility criteria
Qualifiers
Age 18 to 64 years
Signed informed consent
Chronic migraine according to ICHD-3 criteria (32)
At inclusion, patients should retrospectively have at least 15 headache days per month wheof at least 8 migraine days during the last 3 months. This frequency must be confirmed in the headache diary before randomisation to treatment (See below).
Disqualifiers
Pregnancy, planning to get pregnant, inability to use contraceptives (See inclusion criteria, point 8), and lactating
Clinical information on or signs of cholestasis or decreased hepatic or renal function.
High degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator
Hypersensitivity to statins or previous use of statins
Trial design
Treatments tested in this trial
- Atorvastatin 40mg
- Placebo
Treatment groups
Locations
6Sponsors and collaborators
St. Olavs Hospital
Lead sponsor
Haukeland University Hospital
Collaborator
Oslo University Hospital
Collaborator
University Hospital of North Norway
Collaborator
University Hospital, Akershus
Collaborator
Ullevaal University Hospital
Collaborator